International Journal of Head and Neck Surgery

Register      Login

VOLUME 3 , ISSUE 2 ( May-August, 2012 ) > List of Articles

RESEARCH ARTICLE

Novel Dysregulated MicroRNAs in Primary Laryngeal Squamous Cell Cancer

Josena K Stephen, Kang Mei Chen, Veena Shah, Vanessa G Schweitzer, Glendon Gardner, Maria J Worsham, Shaleta Havard

Citation Information : Stephen JK, Chen KM, Shah V, Schweitzer VG, Gardner G, Worsham MJ, Havard S. Novel Dysregulated MicroRNAs in Primary Laryngeal Squamous Cell Cancer. Int J Head Neck Surg 2012; 3 (2):76-81.

DOI: 10.5005/jp-journals-10001-1099

Published Online: 00-08-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction

MicroRNAs (miRNAs) are endogenous, small, noncoding RNAs of 17 to 25 nucleotides that regulate approximately 30% of human genes. They are differentially expressed in various types of cancers compared with noncancerous tissues, suggesting that they may have crucial roles in tumorigenesis. The objective of this study was to identify laryngeal squamous cell cancer (LSCC)-specific miRNAs.

Materials and methods

A retrospective cohort of 10 LSCC and five normal laryngeal squamous epithelium samples were examined using a global miRNA profiling approach (HTG, Tucson, AZ, USA, 800 human miRNAs plus 10 endogenous control miRNAs). The expression status of selected dysregulated miRNAs that were significantly different from normal were verified by real-time quantitative PCR (qPCR).

Results

Twenty-three of the 800 human miRNAs had significantly different expression levels (p < 0.05) between LSCC and normal tissues. Fifteen of the 23 have not been previously reported in HNSCC and include: miR-663b, miR-663, miR-193b, miR-1291, miR-720, miR-191, miR-1224-3p, miR-214, miR- 1285, miR-1207-5p, miR-483-5p, miR-1225-3p, miR-1228, miR-1280 and miR-638. Consistently upregulated miR-31 and miR- 193b and differentially expressed miR-663b in LSCC were verified by qPCR.

Conclusion

The 15 novel miRNAs identified in this exploratory study, pending further confirmation and validation, may have clinical utility as LSCC-specific markers.

How to cite this article

Chen KM, Stephen JK, Havard S Shah V, Gardner G, Schweitzer VG, Worsham MJ. Novel Dysregulated MicroRNAs in Primary Laryngeal Squamous Cell Cancer. Int J Head Neck Surg 2012;3(2):76-81.


PDF Share
  1. MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 2004;116:281-97.
  2. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136:215-33.
  3. MicroRNAs in cancer. Annu Rev Pathol 2009; 4:199-227.
  4. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009; 30:1003-07.
  5. Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 2009;48:569-82.
  6. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105.
  7. MicroRNAs and cancer: What we know and what we still have to learn. Genome Med 2009;1:78.
  8. MicroRNAs in Cancer. Annu Rev Med 2009;60:167-79.
  9. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009;15:3998-4008.
  10. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 2008; 123:2791-97.
  11. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 2009;174: 736-45.
  12. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 2009;18:4818-29.
  13. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009;15:2850-55.
  14. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007;358:12-17.
  15. Salivary microRNA: Discovery, characterization and clinical utility for oral cancer detection. Clin Cancer Res 2009;15:5473-77.
  16. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14:2588-92.
  17. A miR-centric view of head and neck cancers. Biochim Biophys Acta 2011;1816:67-72.
  18. Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay Drug Dev Technol 2002; 1:61-71.
  19. Cancer's Secrets Come Into Sharper Focus New York Times, 2011.
  20. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-49.
  21. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21:1025-30.
  22. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 2010; 16:1129-39.
  23. miRNPs: A novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 2002;16:720-28.
  24. MicroRNA expression profiles of human leukemias. Leukemia 2008; 22:1274-78.
  25. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-29.
  26. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
  27. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-70.
  28. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009;31:642-54.
  29. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin. Gastroenterology 2008;135:257-69.
  30. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72:397-402.
  31. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol 2010;27:685-89.
  32. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166-76.
  33. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010;16:360-64.
  34. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthranceinduced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res 2009;28:64.
  35. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010;176:2520-29.
  36. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010;127:1363-72.
  37. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007;67:6031-43.
  38. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103:3687-92.
  39. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 2010;70:8077-87.
  40. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2007;2: 217-36.
  41. Mammalian mirtron genes. Mol Cell 2007;28:328-36.
  42. MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011;30:1990-2007.
  43. Plexin-B1 is a target of miR- 214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol 2011;43:632-41.
  44. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010;29:3545-53.
  45. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun 2010; 396:435-39.
  46. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008;6:212-21.
  47. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011;117:1630-39.
  48. MicroRNA profiling of human gastric cancer. Mol Med Report 2009;2:963-70.
  49. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009; 4:e5532.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.